At a glance
ClinicalIndex Comparison RecordN/ACompleted· 428 enrolled
Drug / intervention
TheraSpheredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
In Brief
A clinical study evaluating TheraSphere for Colorectal Cancer Metastatic. Completed, enrolled 428 participants across 131 sites in 13 countries.
Detailed Summary
The effectiveness and safety of TheraSphere will be evaluated in patients with colorectal cancer with metastases in the liver, who are scheduled to receive second line chemotherapy. All patients receive the standard of care chemotherapy with or without the addition of TheraSphere.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer Metastatic
CountriesAustria, Belgium, Canada, China, France, Germany, Italy, Poland, Singapore, South Korea, Spain, United Kingdom, United States
CollaboratorsBiocompatibles UK Ltd
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 2011
Enrollment StartJan 2012
Primary CompletionAug 2020
TodayJul 2026
First PostedDec 1, 2011
Enrollment StartJan 1, 2012
Primary CompletionAug 31, 2020
TodayJul 2, 2026
Enrollment to primary: 8.7 yearsPosted 14.6 years ago
Interventions
TheraSpheredevice
yttrium 90 microspheres